Presentations

Machine learning and statistical prediction of overall survival (OS) from pre-dose plasma biomarkers in a randomized phase 2 trial (1801 Part 38) of the GSK-3 inhibitor elraglusib with gemcitabine/nab-paclitaxel (GnP) in metastatic pancreatic ductal adenocarcinoma (mPDAC): application toward patient enrichment

Machine learning and statistical prediction of overall survival (OS) from pre-dose plasma biomarkers in a randomized phase 2 trial (1801 Part 38) of the GSK-3 inhibitor elraglusib with gemcitabine/nab-paclitaxel (GnP) in metastatic pancreatic ductal adenocarcinoma (mPDAC): application toward patient enrichment Read More »

2024-AACR- FOLFIRINOX with glycogen synthase kinase-3 beta (GSK-3β) inhibitor elraglusib and transforming growth factor-β (TGFβ) inhibitor losartan in untreated metastatic pancreatic ductal adenocarcinoma (PDAC): interim analysis of safety cohort

2024-AACR- FOLFIRINOX with glycogen synthase kinase-3 beta (GSK-3β) inhibitor elraglusib and transforming growth factor-β (TGFβ) inhibitor losartan in untreated metastatic pancreatic ductal adenocarcinoma (PDAC): interim analysis of safety cohort Read More »